Allianz Asset Management
LEGN icon

Allianz Asset Management’s Legend Biotech LEGN Stock Holding History

Allianz Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$549K Buy
+19,000
New +$513K ﹤0.01% 1982
2025
Q4 		– Sell
-12,900
Closed -$421K – 2046
2025
Q3 		$421K Hold
12,900
– – ﹤0.01% 1877
2025
Q2 		$458K Buy
+12,900
New +$418K ﹤0.01% 1844
2024
Q4 		– Sell
-14,121
Closed -$688K – 2284
2024
Q3 		$688K Buy
+14,121
New +$752K ﹤0.01% 1767
2024
Q2 		– Sell
-9,941
Closed -$558K – 2201
2024
Q1 		$558K Sell
9,941
-7,700
-44% -$464K ﹤0.01% 1589
2023
Q4 		$1.06M Buy
17,641
+8,693
+97% +$551K ﹤0.01% 1575
2023
Q3 		$601K Hold
8,948
– – ﹤0.01% 1865
2023
Q2 		$618K Buy
+8,948
New +$585K ﹤0.01% 1680
2022
Q3 		– Sell
-252,464
Closed -$13.9M – 2028
2022
Q2 		$13.9M Sell
252,464
-60,552
-19% -$2.56M 0.01% 795
2022
Q1 		$11.4M Buy
313,016
+76,334
+32% +$3.02M 0.01% 954
2021
Q4 		$11M Buy
+236,682
New +$12M 0.01% 959

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Allianz Asset Management's LEGN Position: Q2 2026 in Review

Allianz Asset Management opened a new position in Legend Biotech (LEGN) in Q2 2026: 19,000 shares worth $549K. The stake represents ﹤0.01% of the portfolio and ranks #1982 among its holdings. This is a return to the name: Allianz Asset Management previously reported a position in LEGN as recently as Q3 2025.

Allianz Asset Management first reported a position in LEGN in Q4 2021 and has held it in 11 quarters since. The position peaked at $13.9M in Q2 2022. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Allianz Asset Management held 19,000 shares of Legend Biotech worth $549K as of Q2 2026.
  • Legend Biotech was a new Allianz Asset Management position in Q2 2026.
  • Legend Biotech made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1982 holding.
  • Allianz Asset Management first reported a position in Legend Biotech in Q4 2021 and has held it in 11 quarters since.
  • Allianz Asset Management's Legend Biotech position peaked at $13.9M in Q2 2022.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.